Theriva™ biologics to present preclinical data supporting the potential synergy of vcn-01 and first-line pancreatic cancer chemotherapy regimens at the american society for cell and gene therapy 27th annual meeting

– lead product candidate, vcn-01 in combination with liposomal irinotecan demonstrated enhanced anti-tumor effects in a human pancreatic mouse xenograft –

TOVX Ratings Summary

TOVX Quant Ranking